Stoke Therapeutics Files 8-K Report

Ticker: STOK · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1623526

Stoke Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyStoke Therapeutics, Inc. (STOK)
Form Type8-K
Filed DateJan 7, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, regulatory-filing

TL;DR

Stoke Therapeutics filed an 8-K, mostly financial docs. Nothing major revealed yet.

AI Summary

On January 7, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and exhibits, which are essential for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or adverse events.

Key Players & Entities

  • Stoke Therapeutics, Inc. (company) — Registrant
  • January 7, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-38938 (identifier) — Commission File Number
  • 47-1144582 (identifier) — IRS Employer Identification No.
  • 45 Wiggins Ave (address) — Address of Principal Executive Offices
  • Bedford (location) — City
  • Massachusetts (location) — State
  • 01730 (zip_code) — Zip Code
  • (781) 430-8200 (phone_number) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing by Stoke Therapeutics, Inc.?

The filing is a Current Report (8-K) that includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, with the earliest reported event date being January 7, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 7, 2025.

What is Stoke Therapeutics, Inc.'s state of incorporation and commission file number?

Stoke Therapeutics, Inc. is incorporated in Delaware and has a Commission File Number of 001-38938.

Where is Stoke Therapeutics, Inc.'s principal executive office located?

Stoke Therapeutics, Inc.'s principal executive office is located at 45 Wiggins Ave, Bedford, Massachusetts, 01730.

Does the filing mention any specific new material events or financial results?

Based on the provided excerpt, the filing is primarily a notification of the report's contents (Regulation FD, Other Events, Financial Statements and Exhibits) and does not detail specific new material events or financial results.

Filing Stats: 1,137 words · 5 min read · ~4 pages · Grade level 15.1 · Accepted 2025-01-07 07:06:01

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 7, 2025 99.2 Webinar Presentation dated January 7, 2025 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the design, timing and results of the Phase 3 study; and the timing and expected progress of data readouts, regulatory meetings, regulatory decisions and other presentations. Statements including words such as "expect," "plan," "will," "continue" or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including zorevunersen; the timing of data readouts and interim and final results of preclinical and clinical trials; the receipt and timing of potential regulatory decisions; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company's ability to fund development activities and achieve development goals, including expectations regarding its collaboration with Acadia Pharmaceuticals; the Company's ability to protect its intellectual property; the direct or indirect impact of global business, political and macroeconomic conditions, including inflation, interest rate volatility

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: January 7, 2025 By: /s/ Thomas E. Leggett Thomas E. Leggett Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.